La vendita allo scoperto per NV5 Global dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di NV5 Global. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

NV5 Global (NASDAQ:NVEE) Azioni, Report sulle vendite allo scoperto

NV5 Global

NV5 Global Inc is a provider of technology, conformity assessment, and consulting solutions to public and private sector clients in the infrastructure, utility services, construction, real estate, environmental, and geospatial markets, operating nationwide and abroad. The Company's clients include the U.S. Federal, state and local governments, and the private sector. It also serve quasi-public and private sector clients from the education, healthcare, utility services, and public utilities, including schools, universities, hospitals, health care providers, and insurance providers. The operating business segments are Infrastructure, Building, Technology & Sciences, and Geospatial Solutions. The maximum revenue derives from the infrastructure segment.

NV5 Global Inc

Electric vehicle stocks Rivian Automotive Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) and Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) are in the spotlight Wednesday after the pair of EV makers reported <a href="https://www.benzinga.com/news/earnings/25/05/45236756/rivian-q1-earnings-double-beat-record-gross-profit-delivery-estimates-lowered-on-tariff-concerns">first-quarter financial results</a>.
RIVN Q1 Earnings: Rivian reported first-quarter revenue of $1.24 billion, beating analyst <a href="http://benzinga.com/quote/rivn/earnings">estimates</a> of $1 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported a first-quarter loss of 48 cents per share, beating estimates for a loss of 87 cents per share. 
Rivian said it produced 14,611 vehicles in the first quarter and delivered 8,640 vehicles. The company expects to deliver 40,000 to 46,000 vehicles in 2025, down from prior guidance of 46,000 to 51,000. Rivian also noted that its R2 platform is set to begin production in the first half of 2026.
&#8220;This quarter we hit our second consecutive gross profit and our highest gross profit to date at $206 million. We have continued to make significant progress on R2, including vehicle validation builds underway and our Normal, Illinois manufacturing facility expansion on track,&#8221; said RJ Scaringe, founder and CEO of Rivian.
Following the print, Needham and Wells Fargo analysts <a href="https://www.benzinga.com/analyst-stock-ratings">lowered price targets</a> to $16 and $13, respectively. Cantor Fitzgerald analysts maintained a $15 target.
Check This Out: <a href="https://www.benzinga.com/25/05/45245613/rivian-ceo-rj-scaringe-says-donald-trumps-tariffs-could-increase-costs-by-a-couple-of-thousand-as-company-slashes-delivery-projections">Rivian CEO RJ Scaringe Says Donald Trump&#8217;s Tariffs Could Increase Costs By &#8216;A Couple Of Thousand,&#8217; Slashes Delivery Projections</a>
LCID Q1 Earnings: Lucid reported first-quarter revenue of $235.05 million, missing <a href="https://www.benzinga.com/quote/LCID/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a> of $250 million. The company reported a first-quarter loss of 20 cents per share, beating analyst estimates for a loss of 23 cents per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Lucid said it produced 2,212 vehicles in the first quarter and delivered 3,109 vehicles. The production number doesn't include more than 600 vehicles in transit to Saudi Arabia. The company continues to expect to produce approximately 20,000 vehicles in 2025.
"Lucid Gravity is beginning to arrive in more customers' driveways and at our studios, and combined with our progress toward future initiatives, our company is well-positioned for future success,&#8221; said Marc Winterhoff, interim CEO of Lucid.
Following the print, Cantor Fitzgerald analysts reiterated a Neutral rating with a price target of $3.
RIVN, LCID Price Action: At the time of publication, Rivian shares were down 0.26% at $13.54 and Lucid shares were up 1.07% at $2.35, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45244989/lucid-group-q1-2025-earnings-tesla-rival-announces-58-increase-in-deliveries-plans-to-introduce-a-mid-size-platform-in-2026">Tesla-Rival Lucid Announces 58% Increase In Deliveries, Plans To Introduce Mid-Size Platform In 2026</a></li>
</ul>
Photos: courtesy of Rivian &amp; Lucid.

Earnings

News

Guidance

Movers

LCID

RIVN

What's Going On With EV Stocks Rivian, Lucid On Wednesday?

Wedbush analyst Matt Bryson maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Outperform and raises the price target from $115 to $120.

Price Target

Analyst Ratings

Wedbush Maintains Outperform on Advanced Micro Devices, Raises Price Target to $120

ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate ALX Oncology Holdings to report an earnings per share (EPS) of $-0.34.
Investors in ALX Oncology Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.05, leading to a 19.08% drop in the share price on the subsequent day.
Here's a look at ALX Oncology Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.39</td>
<td>-0.78</td>
<td>-0.77</td>
<td>-0.84</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.44</td>
<td>-0.45</td>
<td>-0.62</td>
<td>-0.57</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-19.0%</td>
<td>-4.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746634197_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of ALX Oncology Holdings were trading at $0.5037 as of May 06. Over the last 52-week period, shares are down 97.14%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ALXO/earnings">To track all earnings releases for ALX Oncology Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALXO

What's Next: ALX Oncology Holdings's Earnings Preview

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Nektar Therapeutics to report an earnings per share (EPS) of $-0.18.
The market awaits Nektar Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $0.04, leading to a 0.56% drop in the share price the following trading session.
Here's a look at Nektar Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.19</td>
<td>-0.21</td>
<td>-0.20</td>
<td>-0.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.15</td>
<td>-0.18</td>
<td>-0.25</td>
<td>-0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>-8.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746634186_0.png" alt="eps graph" />
<h3>Market Performance of Nektar Therapeutics's Stock</h3>
Shares of Nektar Therapeutics were trading at $0.642 as of May 06. Over the last 52-week period, shares are down 61.72%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Insights on Nektar Therapeutics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Nektar Therapeutics.
A total of 4 analyst ratings have been received for Nektar Therapeutics, with the consensus rating being Buy. The average one-year price target stands at $5.25, suggesting a potential 717.76% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of scPharmaceuticals and Aclaris Therapeutics, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for scPharmaceuticals, with an average 1-year price target of $16.5, suggesting a potential 2470.09% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Aclaris Therapeutics, with an average 1-year price target of $15.0, suggesting a potential 2236.45% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary outlines pivotal metrics for scPharmaceuticals and Aclaris Therapeutics, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nektar Therapeutics</td>
<td>Buy</td>
<td>22.15%</td>
<td>$21.20M</td>
<td>13.25%</td>
</tr>
<tr>
<td>scPharmaceuticals</td>
<td>Buy</td>
<td>99.31%</td>
<td>$8.19M</td>
<td>-85.60%</td>
</tr>
<tr>
<td>Aclaris Therapeutics</td>
<td>Outperform</td>
<td>-47.58%</td>
<td>$-90K</td>
<td>-67.59%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Nektar Therapeutics ranks highest in gross profit among its peers. It is in the middle for consensus rating and revenue growth. However, it has the highest return on equity compared to its peers.
<h3>Delving into Nektar Therapeutics's Background</h3>
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
<h3>Unraveling the Financial Story of Nektar Therapeutics</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Nektar Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 22.15%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Nektar Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 24.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Nektar Therapeutics's ROE excels beyond industry benchmarks, reaching 13.25%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Nektar Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.37% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Nektar Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.69.
<a href="https://www.benzinga.com/quote/NKTR/earnings">To track all earnings releases for Nektar Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NKTR

Nektar Therapeutics's Earnings: A Preview

Keefe, Bruyette &amp; Woods analyst Ryan Tomasello maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) with a Market Perform and lowers the price target from $80 to $76.

Keefe, Bruyette & Woods Maintains Market Perform on Zillow Gr, Lowers Price Target to $76

<a href="https://news.bloomberglaw.com/antitrust/us-appeals-court-affirms-microsoft-activision-merger?context=search&amp;index=0">https://news.bloomberglaw.com/antitrust/us-appeals-court-affirms-microsoft-activision-merger?context=search&amp;index=0</a>

General

MSFT

'US Appeals Court Affirms Microsoft-Activision Merger'- Bloomberg Law

Keefe, Bruyette &amp; Woods analyst Bose George maintains UWM Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NYSE">UWMC</a>) with a Outperform and lowers the price target from $7.5 to $6.5.

UWMC

Keefe, Bruyette & Woods Maintains Outperform on UWM Holdings, Lowers Price Target to $6.5

Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is quietly entering the AI coding assistant space, and it's doing it alongside <a href="https://www.benzinga.com/25/05/45160136/nvidia-blasts-anthropic-for-backing-stricter-chip-bans-on-china-focus-on-innovation-than-tell-tall-tales">Anthropic</a>, one of the most heavily funded artificial intelligence startups in the world.
Backed by Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a $4 billion investment, including an initial $1.25 billion with an option for an additional $2.75 billion, and Google, with a $500 million upfront investment and a commitment of up to $2 billion total, as reported by<a href="https://www.reuters.com/technology/google-agrees-invest-up-2-bln-openai-rival-anthropic-wsj-2023-10-27/"> Reuters</a>, Anthropic is now collaborating with Apple to launch a new <a href="https://www.benzinga.com/news/25/05/45184302/bill-gates-daughter-launches-phia-a-850k-ai-powered-fashion-app-with-backing-from-kris-jenner-and-desiree-gruber">AI</a>-enhanced coding tool built into Xcode, according to<a href="https://www.bloomberg.com/news/articles/2025-05-02/apple-anthropic-team-up-to-build-ai-powered-vibe-coding-platform"> Bloomberg</a>.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
The tool will rely on Anthropic's Claude Sonnet, a cutting-edge language model capable of writing, editing, and executing code with advanced reasoning and troubleshooting abilities, Bloomberg reports. Internally dubbed a "vibe-coding" interface, the assistant is designed to let Apple engineers build full software components using natural language, which is a step forward in the tech giant&#8217;s growing effort to embed generative AI into its core development tools.
According to Bloomberg, this marks one of Apple's first direct partnerships with a major AI player amid growing competition from Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), which has already integrated OpenAI's GPT technology into GitHub Copilot, a popular AI pair-programming assistant.
Trending: Donald Trump just announced a $500 billion AI infrastructure deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share">here's how you can invest in the entertainment market's next big disruptor at $2.25 per share</a>.
<h2 class="wp-block-heading">Claude Sonnet Brings Amazon and Google's Firepower Into Apple's Walled Garden</h2>
With funding exceeding $7 billion,<a href="https://www.builtinsf.com/articles/anthropic-launches-claude-3-20240304"> Built In San Francisco</a> reports, and strategic backing from two giants, Claude is quickly positioning itself as a rival to OpenAI's GPT-4, according to<a href="https://www.tomsguide.com/ai/i-tested-chatgpt-4o-vs-claude-3-7-sonnet-with-5-tough-prompts-and-this-one-crushed-the-competition"> Tom&#8217;s Guide</a>. The Claude family of models is known for high performance in reasoning, code generation, and low hallucination rates, making it an ideal choice for professional-level AI coding applications,<a href="https://www.anthropic.com/claude"> Anthropic</a>&#8216;s website states.
Apple's decision to integrate Claude Sonnet into Xcode represents a notable departure from its typical vertically integrated approach. According to Bloomberg, this tool will initially be used internally, but discussions are ongoing about a broader rollout to external developers. Developers will be able to request bug fixes, test interface elements, or even write entire blocks of Swift code using natural language prompts, Bloomberg reports.
While Apple previously teased a native Swift Assist tool in 2024 according to<a href="https://www.macrumors.com/2025/03/13/apple-announced-swift-assist-wwdc24-so-where-is-it/"> MacRumors</a>, it was never released. Reports now suggest that Claude Sonnet may quietly replace Swift Assist behind the scenes as Apple ramps up internal AI infrastructure and evaluates the tool's long-term integration potential, Bloomberg writes.
See Also: Shark Tank's Kevin O'Leary called Missing Ring his biggest mistake — Don't repeat history—<a href="https://www.benzinga.com/money/big-tech-has-spent-billions-acquiring-ai-smart-home-startups-one-company-stands-to-benefit-and-has-already-made-10-million">invest in RYSE at just $1.90/share.</a>
<h2 class="wp-block-heading">A Growing Battlefield in AI-Driven Development</h2>
With Amazon leveraging Claude to power enterprise-level AWS offerings, Google collaborating on AI safety research, and Apple&#8217;s plans to integrate the tool into Xcode, the Claude ecosystem is expanding rapidly across industries, now including one of the most powerful hardware companies in the world.
According to Bloomberg, Apple remains cautious about a public rollout but sees strategic value in internal deployment to sharpen its AI expertise. Whether or not the Claude-powered Xcode assistant becomes public, this partnership may reflect Apple's acknowledgment that external AI platforms will likely play a growing role in the future of its software tools.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market">Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

AAPL

AMZN

Apple Teams Up With AI Startup Anthropic To Integrate Claude Sonnet Into Xcode, Challenging Microsoft's GitHub Copilot

America's student loan bill just clocked in at an eye-popping $1.77 trillion, leaving families and policymakers scrambling for answers, according to <a href="https://www.nerdwallet.com/article/loans/student-loans/student-loan-debt">NerdWallet.</a> But for personal finance expert Dave Ramsey, the culprit isn't just broken systems — it&#8217;s parenting.&nbsp;
"It's not a student loan crisis, we have a parenting crisis," Ramsey said on a 2019 episode of "<a href="https://www.youtube.com/watch?v=T_rYd_88Tkk">The Dave Ramsey</a>" show, arguing that inadequate financial education at home often leads to financial struggles later in life.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
Ramsey's remarks mirror the message in his 2021 documentary<a href="https://www.ramseysolutions.com/shows/borrowed-future"> "Borrowed Future</a>," where his team investigates how young adults fall into massive debt traps before they even turn 20. It also explored how colleges encourage easy access to loans, but he argues that it&#8217;s ultimately up to families to question and plan better — avoiding the blind signing of massive obligations.
<h2 class="wp-block-heading">Student Loan Numbers Reach New Heights</h2>
According to the <a href="https://educationdata.org/student-loan-debt-statistics">Education Data Initiative</a>, more than 42.7 million Americans have student loans, with the average borrower carrying a balance of around $38,000. The outstanding federal student loan balance totals $1.693 trillion.
To put it in perspective, that figure ($1.63 trillion) surpasses the annual GDP of some mid-sized nations. According to <a href="https://www.bankrate.com/loans/student-loans/student-loan-debt-statistics/">Bankrate</a>, it now makes up about 9% of all consumer debt in the U.S. The <a href="https://educationdata.org/average-student-loan-payment">Education Data Initiative</a> reports that this financial burden has increasingly squeezed young professionals, with monthly payments often eating up to 10% of their income.
Trending: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
<h2 class="wp-block-heading">Ramsey's Parenting Callout</h2>
Ramsey responded to a parent seeking advice on helping a wealthy, budget-averse daughter during an April 17 episode of "<a href="https://www.youtube.com/watch?v=l8fFUhmmRPI">The Dave Ramsey" </a>show.
Co-host John Delony weighed in, explaining, "Your daughter is acting like an 18-year-old," while Ramsey doubled down that the real problem starts with parents failing to model financial responsibility early.&nbsp;
Through his lens, parents should be the &#8220;first line of defense&#8221; — teaching saving, budgeting, and debt avoidance years before the college application process even begins.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<h2 class="wp-block-heading">Collections Resume Amid Big Policy Shifts</h2>
The timing of Ramsey's statement wasn't random. On April 21, the Department of Education <a href="https://www.ed.gov/about/news/press-release/us-department-of-education-begin-federal-student-loan-collections-other-actions-help-borrowers-get-back-repayment">announced </a>that collections would restart for borrowers who are in default.&nbsp;
This marks a major shift after the original student loan payment pause, created under the CARES Act in March 2020, was extended through the Biden administration. As the Office of<a href="https://studentaid.gov/announcements-events/default-collections-resume-2025"> Federal Student Aid</a> outlined, borrowers who had defaulted will soon face wage garnishment and tax refund seizures once again.
Then, in January, the <a href="https://bidenwhitehouse.archives.gov/briefing-room/statements-releases/2025/01/13/statement-from-president-joe-biden-on-approving-student-debt-cancellation-for-over-5-million-americans/">Biden administration</a> also celebrated canceling $189 billion in student loans for over 5 million Americans. Adding to the urgency, <a href="https://www.investopedia.com/student-loan-borrowers-in-default-face-credit-hits-wage-garnishment-due-to-confusing-collection-policies-11722143">over 5 million borrowers</a> in default will face renewed collections starting May 5, including wage garnishment and tax refund seizures.
Read Next:
<ul>
<li>Donald Trump just announced a $500 billion AI infrastructure deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share">here's how you can invest in the entertainment market's next big disruptor at $2.25 per share</a>.</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Student Loan Debt Hits $1.77 Trillion—Dave Ramsey Blames Parents, Not Policies: 'It's Not A Student Loan Crisis, We Have A Parenting Crisis'

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains The Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) with a Market Perform and raises the price target from $171 to $173.

Keefe, Bruyette & Woods Maintains Market Perform on The Hanover Insurance Gr, Raises Price Target to $173

<a href="https://www.wsj.com/world/greenland-spying-us-intelligence-809c4ef2" title="https://www.wsj.com/world/greenland-spying-us-intelligence-809c4ef2">https://www.wsj.com/world/greenland-spying-us-intelligence-809c4ef2</a>

Macro Economic Events

Politics

Global

Economics

EDEN

Reuters Reports Danish Foreign Minister Saying, Will Call On Acting U.S. Ambassador To Denmark To Discuss WSJ Report About U.S. Ordering Intelligence Agencies to Step Up Spying on Greenland

Wedbush analyst Scott Devitt maintains DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Neutral and raises the price target from $190 to $200.

DASH

Wedbush Maintains Neutral on DoorDash, Raises Price Target to $200

Economist Justin Wolfers says the real pain from new import tariffs is likely to hit shoppers' wallets — and possibly the broader economy — long before store shelves go bare. 
What Happened: "I'm not sure that tariffs will lead to shortages," he posted on X. "They might lead to price hikes, or a recession instead."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I&#39;m not sure that tariffs will lead to shortages. They might lead to price hikes, or a recession instead. Let&#39;s dig into the <a href="https://twitter.com/hashtag/economics101?src=hash&amp;ref_src=twsrc%5Etfw">#economics101</a> of supply shocks. <a href="https://t.co/Qyrxbe6TCH">pic.twitter.com/Qyrxbe6TCH</a>
&mdash; Justin Wolfers (@JustinWolfers) <a href="https://twitter.com/JustinWolfers/status/1919871427257237926?ref_src=twsrc%5Etfw">May 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Appearing on MSNBC, Wolfers laid out three paths: "Everything's-going-to-be-sold-out… that's one possibility, but it's not the only one,&#8221; he says. &#8220;Another possibility&#8230; is the reason that they&#8217;re not ordering this stuff is they realize they&#8217;re going to have to jack up their prices and they&#8217;ll jack them up so high that not many people are gonna wanna buy stuff. So it could be we&#8217;ve got a big adverse price shock coming and you&#8217;re going to get some sticker shock coming right at you,&#8221; Wolfers adds.
A professor of public policy and economics at the University of Michigan, Wolfers says: &#8220;The third possibility is that the President may well plunge the economy into recession.&#8221;
See also: <a href="https://www.benzinga.com/25/05/45249388/we-dont-have-to-sign-deals-says-trump-amid-mounting-pressure-over-trade-talks-i-wish-theyd-stop-asking">Trump Says &#8216;We Don&#8217;t Have To Sign Deals&#8217; Amid Mounting Pressure Over Trade Talks Outcome: &#8216;I Wish They&#8217;d…Stop Asking&#8217;</a>
Research backs him up. Academic studies of the 2018 trade‑war levies <a href="https://www.aeaweb.org/articles?id=10.1257%2Fjep.33.4.187&amp;">found</a> virtually the entire duty cost was passed to U.S. consumers in higher prices, with no evidence of widespread stockouts. The Tax Foundation <a href="https://taxfoundation.org/blog/trump-tariffs-prices-long-term-effects/">calculates</a> that broad tariffs "raise prices and lower living standards" even when buyers switch to domestic goods.
Why It Matters: Early warnings are already trickling in. Former Vice President Mike Pence told CNN that sweeping duties could spark a "<a href="https://www.benzinga.com/news/25/05/45214328/mike-pence-warns-trumps-indiscriminate-tariffs-could-trigger-price-shock-and-potential-shortages-keeping-our-kids-toys-affordable-is-part-of-the-american-dream">price shock</a>" — echoing Wolfers' sticker‑shock scenario. Supply‑chain executives, meanwhile, say cascading costs could shave trucking jobs and <a href="https://www.benzinga.com/personal-finance/25/05/45183970/behind-the-empty-docks-how-trumps-145-tariffs-are-gutting-u-s-supply-chains">tip the economy</a> toward contraction by mid‑summer.
Retail experts likewise say certain low‑margin imports such as toys and earbuds <a href="https://www.benzinga.com/markets/25/04/45008049/shoes-toys-apparel-and-earbuds-may-disappear-from-shelves-first-as-us-china-trade-war-disrupts-supply-chains-retail-experts-warn">may vanish</a> first as companies race to reorder ahead of higher duties.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/personal-finance/25/05/45249352/ray-dalio-says-its-too-late-to-escape-tariff-damage-worries-u-s-will-be-bypassed">Ray Dalio Says &#8216;It&#8217;s Too Late&#8217; To Escape Tariff Damage, Worries U.S. &#8216;Will Be Bypassed&#8217;</a>

Government

Regulations

Economist Justin Wolfers Says Tariffs Won't Lead To Shortages, But Explains Why It Might Cause A Recession

Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintains Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) with a Outperform and raises the price target from $250 to $255.

Keefe, Bruyette & Woods Maintains Outperform on Reinsurance Gr, Raises Price Target to $255

Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintains Prudential Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) with a Market Perform and lowers the price target from $120 to $117.

Keefe, Bruyette & Woods Maintains Market Perform on Prudential Financial, Lowers Price Target to $117

Citigroup analyst Thomas Palmer maintains BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) with a Buy and lowers the price target from $90 to $80.

BRBR

Citigroup Maintains Buy on BellRing Brands, Lowers Price Target to $80

Keefe, Bruyette &amp; Woods analyst Tim Switzer maintains Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) with a Outperform and lowers the price target from $12 to $10.

PRTH

Keefe, Bruyette & Woods Maintains Outperform on Priority Tech Holdings, Lowers Price Target to $10

Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNLI#NASDAQ">DNLI</a>) with a Outperform and lowers the price target from $32 to $30.

DNLI

Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30

Biotech

VALN

Valneva SE Announces That The EMA Has Started A Review Of Valneva's Single-Dose Live Attenuated Chikungunya Vaccine IXCHIQ Based On Reports Of Serious Adverse Events In Elderly People

WIIM

TROX

Tronox Holdings shares are trading lower after BMO Capital downgraded the stock from Outperform to Market Perform and lowered its price target from $13 to $7.

Comments

NV5 Global

Vendite allo scoperto

NV5 Global (NASDAQ:NVEE) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO